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336 Predicting future treatment needs from annual review data
L. Thompson1, D.D. Derry1, D.J. Waine1. 1Derriford Hospital, Adult CF Centre,
Plymouth, United Kingdom
Objectives: From April 2012, UK centres will be funded based on treatment patients
needed the 12 months leading up to annual review the previous calendar year. Thus,
funding will be based on data 3−15 months old, potentially underestimating patients’
health needs. We investigated whether data from the previous calendar year (only
3 months old) were better at predicting subsequent treatment needs.
Methods: The following data were collected retrospectively from all patients treated
at our centre from 2008 to 2011: number of in-patient days (IP days), number of
days of iv antibiotics (IV days), and month of annual review. Wilcoxon matched-
pairs signed-rank and Kolgorov–Smirnov tests were used to test whether data from
the previous calendar year were better than annual review data from that year at
predicting treatment needs the following calendar year.
Results: 103 patient-years (41 patients) were analyzed. IP days differed by a mean
2.9 days (range −66 to +132) from the previous calendar year, compared to a mean
3.5 days (range −100 to +144) from annual review. IV days differed by a mean
3.2 days (range −97 to +178) compared to a mean 5.1 days (range −78 to +218).
Differences in the means were not signiﬁcant (p = 0.33, Wilcoxon). When data
were analyzed to look at the variation in treatment band there was no signiﬁcant
difference.
Conclusion: Though treatment needs for some individuals changed dramatically
from year to year, overall the treatment needs of patients in a given calendar year
were reasonably predicted by the treatment given as measured at patients’ previous
annual reviews. There would be no beneﬁt in using calendar year data rather than
annual review data.
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Background: Intravenous (IV) antibiotic (ABX) treatments for CF pulmonary
exacerbations (PEx) are associated with poor lung function. We studied how changes
in CF pulmonary health have affected PEx treatment incidence.
Methods: IV and oral/inhaled (nonIV) ABX PEx treatment incidence from 1995–
2005 stratiﬁed by age group (<6, 6−12, 13−17, 18 yr) was calculated from the
Epidemiologic Study of CF. Modiﬁed sign/symptom scores (range 0−4) associated
with PEx treatment [Rabin et al., Ped. Pulm. 2004; 37: 400] were calculated.
Results: 213,054 PEx ABX treatments occurred over 185,981 patient years (pt-yr)
studied. ABX treatment (Tx) incidence fell 0.07/yr (R2 = 0.85; P< 0.001) from
1.68 Tx/pt-yr in the 18 yr group and 0.04/yr (R2 = 0.74; P< 0.001) in the 13−17 yr
group, while rising 0.03/yr from 0.55 Tx/pt-yr (R2 = 0.63; P = 0.004) in the <6 yr
group, the latter due to a 0.04/yr (R2 = 0.64; P = 0.001) nonIV ABX treatment
increase. Tx incidence was unchanged in the 6−12 yr group. 30,337 PEx were
evaluable for Rabin clinical score. Mean clinical scores at nonIV ABX treatment
dropped 0.01–0.02 units/yr (R2 range 0.34–0.77; P< 0.001 to P = 0.06); IV ABX
treatment score changes showed no pattern by age, with <6 yr group mean scores
dropping 0.03 units/yr (R2 = 0.45; P = 0.02).
Conclusions: PEx ABX treatment incidence changed signiﬁcantly from 1995–2005,
with children receiving more ABX treatments and adults receiving fewer. Clinical
thresholds for intervention declined over the 11-year study period for nonIV ABX
treatment in all age groups, and for IV ABX treatment in patients aged <6. These
data underscore the importance of including nonIV ABX treatments and treatment
thresholds in PEx analyses.
338 Improved life expectancy in cystic ﬁbrosis patients: real progress
or reduced measurement bias?
G. Bellis1, M.-H. Cazes1, A. Parant1. 1Institut National d’Etudes Demographiques
(INED), Paris, France
Objectives: To calculate life expectancy at birth of cystic ﬁbrosis patients in
France (period 1994–2008) and to interpret trends by distinguishing between the
improvement attributable to progress in healthcare and that explained by better
observation and measurement conditions.
Methods: The study population is that of the French Cystic Fibrosis Registry (RFM)
which has recorded individual clinical data on patients since 1992: diagnosis,
vital status, anthropometry and spirometry, bacteriology, morbidity and therapeutic
management.
Mortality was analysed on a cross-sectional basis, using the standard demographic
method of period life tables, taking account of populations and deaths in the RFM
by three-year period: 1993−1994−1995, . . . 2007–2008–2009. Each table provided
the series of ﬁve-year probabilities of dying at different ages, and life expectancies
at each age.
The RFM mortality data were compared with the life tables of the French population
giving, for the past, the same life expectancies at birth.
Conclusions: The increase in life expectancy of cystic ﬁbrosis patients, from
29.4 years in 1994 to 48.8 years in 2008, can be explained by two factors:
– improved patient survival: at the adult ages when the majority of cystic ﬁbrosis
deaths occur (15−35 years), the risks of dying in 2008 were lower than in the
past.
– improved coverage of the RFM, linked to the introduction of neonatal screening
in 2002 and a reorganization of healthcare management for CF patients: this led
to the inclusion of a growing number of adults and of asymptomatic newborns
who were previously unobserved and whose presence has contributed to lowering
the age-speciﬁc risks of dying.
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Background: Normal FEV1 (NFEV1) does not exclude early lung disease in CF.
NFEV1 patients are of special interest for using more accurate techniques to
determine early lung disease. With this survey we aimed to deﬁne these patients
and looked if their characteristics changed over time.
Methods: Retrospective analysis of the Belgian CF Registry (BR) focused on
patients with FEV1%pred 85% (NFEV1). Data were collected from the annual
reports from 1998 to 2008.
Results: CF population increased in time from 566 in 1998 to 1087 in 2008, with
a signiﬁcant increase in adults from 38.5% to 50.3% (p< 0.001). NFEV1 patients
increased from 28.5% in 1998 to 42.7% in 2008 (p< 0.001). This trend, signiﬁcant
in both females and males, was stronger for NFEV1 males (adjusted odds ratio 1.28,
95%CL 1.15 to 1.42). In 1998, 97.3% of NFEV1 patients had a sweat chloride
>60mmol/L; this proportion decreased steadily to 84% in 2008 (p< 0.001). Two
known CFTR mutations were detected in 79.3% of the NFEV1 patients in 1998
versus 85.5% in 2008 (p = 0.002). For F508del/F508del, proportions decreased in
time from 56% in 1998 to 40.4% in 2008 (p< 0.001).
Discussion: A signiﬁcant increase in NFEV1 patients was seen over an 11-year
period, with a signiﬁcant increase in adults. This could be explained by the
signiﬁcant increase in NFEV1 patients with atypical CF. A more detailed genetic
analysis of CFTR over 11 years explains the increase in patients with two known
CFTR mutations. Separate analysis of the F508del/F508del adults is needed to
conclude that improved CF care over 11 years had also its impact on the increased
proportion of NFEV1 CF patients.
